Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 08/31
| 02-2025 | 11-2024 | 08-2024 | 05-2024 | 02-2024 | |
| Sales | 174 | 184 | 84 | 84 | 145 |
| Cost of Goods | N/A | 3 | N/A | N/A | N/A |
| Gross Profit | 174 | 181 | 84 | 84 | 145 |
| Operating Expenses | 2,925 | 2,875 | 2,287 | 1,827 | 813 |
| Operating Income | -2,751 | -2,691 | -2,203 | -1,743 | -668 |
| Other Income | 34 | -16 | 17 | -41 | 15 |
| Pre-tax Income | -2,717 | -2,707 | -2,187 | -1,784 | -653 |
| Net Income Continuous | -2,717 | -2,707 | -2,187 | -1,784 | -653 |
| Minority Interests | -4 | -3 | -2 | -3 | -3 |
| Net Income | $-2,713 | $-2,704 | $-2,185 | $-1,782 | $-650 |
| EPS Basic Total Ops | -0.15 | -0.16 | -0.15 | -0.13 | -0.06 |
| EPS Basic Continuous Ops | -0.16 | -0.16 | -0.15 | -0.13 | -0.06 |
| EPS Diluted Total Ops | -0.15 | -0.16 | -0.15 | -0.13 | -0.06 |
| EPS Diluted Continuous Ops | -0.16 | -0.16 | -0.15 | -0.13 | -0.06 |
| EPS Diluted Before Non-Recurring Items | -0.15 | -0.16 | -0.15 | N/A | N/A |
| EBITDA(a) | $-2,749 | $-2,658 | $-2,187 | $-1,728 | $-652 |